Search PubMed⌕ Search

Biomedical subjects

S Matsuda

Publications and source records attributed to S Matsuda.

At least 649 records · Page 36Linked to original sources
PubMed1985

[Phase I clinical studies of S6472 (sustained release preparations of cefaclor)].

Current (regular) preparation of cefaclor (CCL) require the 3-time-a-day administration. S6472 (sustained release preparation) which can be used with the twice-a-day administration in the morning and the evening is capsule and granule preparations consisting of 40% of nonenteric and 60% of enteric coated granules of CCL. Phase I clinical studies of S6472 were conducted in 12 nonfasted healthy adult male volunteers with cross over method using a single dose of 375 mg in capsule and granule forms of S6472, and 250 mg in capsule form of regular CCL as a control drug. The volunteers received the 3 preparations at 1-week interval. The summary of the results from the above studies is as follows: Grouping of the volunteers. The 12 volunteers were divided into 3 groups (each group consists of 4 volunteers) and there were no significant differences between each group regarding background factors of the volunteers. Tolerance. None of the volunteers who received the 3 preparations at 1-week interval complained of subjective abnormalities. No abnormalities which are considered to be due to S6472 and regular CCL were found in the clinical laboratory tests carried out before the administration and 1 week after the completion of the studies. Plasma level. There were no significant differences between capsule and granule forms of S6472 regarding Cmax and AUC, and it was confirmed that bioavailability of both preparations was the same. It was also confirmed that plasma levels of the 2 preparations of S6472 were maintained for longer period of time than those of regular CCL. Urinary excretion. Mean urine levels of the 2 preparations of S6472 every 2 hours after the administration were confirmed to be maintained for longer period of time than those of regular CCL. There were no significant differences between the 2 preparations of S6472 regarding urinary recovery rate. However, the significant differences between the 2 preparations of S6472 and regular CCL were observed. Urinary recovery rate of the 2 preparations of S6472 was 87 approximately 88% of that of regular CCL.

Adult↗
PubMed1985

[Absorption and excretion studies of S6472 (sustained release preparations of cefaclor)].

In order to see absorption and excretion of S6472 (sustained release preparations of cefaclor (CCL], 3 studies regarding, 1) influence of meals (single dose of 375 mg in capsule form), 2) dose response (single dose of 375 mg vs. 750 mg in granule form) and 3) continuous administration (twice-a-day administration of 750 mg in granule form for 8 days) were conducted in 15 healthy adult male volunteers using capsule and granule forms of S6472. The following is the summary of the results from the above studies: Tolerance. In the above 3 studies, none of the 15 volunteers complained of subjective abnormalities. In the clinical laboratory tests performed before the administration of S6472 and at the next day of the completion of the studies, the values from the laboratory tests were within normal range. Influence of meals. The average time for peak plasma level of CCL and decrease in the plasma level following the administration of S6472 were the fastest in the fasted volunteers, followed by the volunteers with light meals and usual meals. From this, it was confirmed that plasma levels of CCL were maintained for longer period of time in the non-fasted volunteers than in the fasted volunteers. In the volunteers who had light and usual meals, the peak plasma levels, AUC of the plasma levels and urinary recovery rate were almost the same. Influence by amount of meals was scarcely observed. Dose response. Mean serum levels and their AUC in the volunteers receiving 750 mg of S6472 were approximately twice as much as those in the volunteers receiving 375 mg of S6472, and dose response between the 2 doses was confirmed. Continuous administration. Mean serum levels and their AUC at the first dose and the 15th dose (final dose) were almost the same. In the continuous administration of S6472 for 8 days (15 doses), no accumulation of CCL in the body was observed.

Adult↗
PubMed1984

Detection of human T-cell leukemia virus antibodies in a Japanese T-cell leukemia patient with hypercalcemia.

A T-cell (KH-2) from a Japanese T-cell leukemia patient with hypercalcemia has been characterized and shown to be similar in its properties to Human T-cell leukemia virus (HTLV)-positive T-cell lines from T-cell leukemia patients from different parts of the world. The HTLV isolated from the Japanese T-cell leukemia patient with hypercalcemia belongs to the HTLV family and has properties similar to HTLV from T-cell leukemia patients from the United States, Israel, and the Caribbean.

Antibodies, Viral↗
PubMed1984

Synaptogenesis in the chick cervical cord and possible initial central pathways from dorsal root fibers to motor neurons--Golgi and electron microscopic studies.

The early formation of neuronal connections in the cervical cord of the chick embryo was studied by observing axonal courses at stages 24 and 27 with Golgi preparations and the distribution of synapses at stages 22, 25 and 27 with electron microscopy. Early developing interneurons sent their axon to the ventral and lateral funiculi. Synapses were observed in the transit part from ventral to lateral funiculus at stage 22, in the ventral funiculus, the ventral part of the lateral funiculus and the dorsal funiculus at stage 25. It was suggested that the neuronal pathways from dorsal root fibers to motor neurons were first formed at stage 25 with the intervention of interneurons.

Animals↗
PubMed1984

Prenatal development of the rat dorsal root ganglia. A scanning electron-microscopic study.

This study describes three-dimensional aspects of the development and pseudo-unipolarization of neuroblasts and the maturation of satellite cells in prenatal rat dorsal root ganglia, using scanning electron microscopy, after removal of extracellular connective tissue components by trypsin digestion and HC1 hydrolysis. At 14 days of gestation, the vast majority of neurons are spindle-shaped or bipolar and only 3% are unipolar, while at 16 and 18 days this percentage has increased to 30% and 91%, respectively. The initial portions of the central and peripheral neuronal processes gradually approach each other and form a common initial portion. Finally, the cytoplasm of this common initial portion becomes thinner and elongates to form the stem process of the mature cell. Satellite cells are present from the beginning of the period studied, but intricate networks of branching satellite cell processes only develop after about day 17.

Animals↗
PubMed1984

Effect of tumor promoters on human T cell leukemia/lymphoma virus (HTLV)-structural protein induction in adult T-cell leukemia cells.

We assayed the capacity of tumor promoters to induce human T-cell leukemia/lymphoma virus (HTLV) structural proteins p19 and p24 from the HTLV genome-carrying adult T-cell leukemia (ATL) cell lines, MT-1 and KH-2Lo, and fresh ATL cells. Among the tested substances, 12-O-tetradecanoyl phorbol-13-acetate (TPA), 12-hexadecanoyl-phorbol-13-acetate (HPA) and teleocidin induced HTLV structural protein p19 and p24. This suggests that certain environmental substances, especially those known to be tumor promoters, may activate the HTLV-gene in ATL cells.

Adult↗
PubMed1984

Interrelationships between the renin-angiotensin-aldosterone system and sympathetic and dopaminergic activities in elderly subjects.

The interrelationships between the renin-aldosterone system and the sympathetic and dopaminergic activities were studied by measuring the plasma renin activity (PRA), plasma aldosterone concentration (PAC), serum prolactin (PRL) concentration, and 24 hr-urinary excretions of adrenaline (Ad), noradrenaline (NA) and dopamine (DA) in elderly normotensive subjects aged 60 to 90 yrs. The PAC showed a significant correlation with NA in the urine (gamma = 0.694, n = 24, p less than 0.001). The PRA also tended to correlate with NA in the urine, although the degree was weak and not significant. The serum PRL concentration showed a significant correlation with DA in the urine (gamma = 0.447, n = 24, p less than 0.05). No significant correlation was observed between DA and PRA or PAC, and between the serum PRL concentration and PRA or PAC. From these results, it is shown that the renin-aldosterone system has a relation to urinary NA excretion, and the existence of an interrelationship between the central dopaminergic activity and urinary DA excretion is suggested.

Aged↗
PubMed1984

Study of the interrelationship between dopaminergic activity and potassium ion.

The present study was designed to examine the interrelationship between dopaminergic neuron activity and potassium ion in the normotensive elderly subjects with a stable physical condition. Potassium chloride loaded intravenously (40mEq/day) in 5 subjects increased urinary excretions of Na (p less than 0.01) and dopamine. Furosemide administered orally (20mg/day) in 5 subjects increased urinary excretions of Na (p less than 0.05), dopamine (p less than 0.01) and K. Spironolactone administered orally (75mg/day) in 5 subjects brought an increase of urinary excretion of Na and a decrease of urinary excretions of K and dopamine, although these changes were not statistically significant. Metoclopramide, a dopamine antagonist, administered orally (15mg/day) in 5 subjects brought about a tendency of decrease in urinary excretions of Na and K. Between urinary amounts of K and dopamine, a positive correlation (gamma = 0.702, p less than 0.001, n = 22) was recognized. From these results, the change of the excretion of dopamine seemed to be parallel with that of K, and therefore it is suggested that a mechanism involved in the excretion of dopamine into the urine has a close relationship with that excreting K. The possible mechanisms are discussed.

Aged↗
PubMed1984

[Concentrations of cefotaxime in serum and myocardial tissue].

Serum and myocardial concentrations of cefotaxime (CTX) were measured in 20 adult patients undergoing cardiac surgery. To all of these patients 1.0 g of CTX was given intravenously (in the range of 13.7--29.0 mg/kg) at the beginning of operation. The serum concentrations of CTX were determined at 5, 10, 30, 60 minutes and 120 minutes after administration. Myocardial concentrations of CTX were also determined at about 30 minutes (group I), 60 minutes (group II) and 120 minutes (group III). The following results were obtained. Average serum CTX concentrations were 132.8 +/- 34.1 micrograms/ml at 5 minutes, 92.0 +/- 23.1 micrograms/ml at 10 minutes, 44.6 +/- 12.3 micrograms/ml at 30 minutes, 24.5 +/- 7.7 micrograms/ml at 60 minutes and 12.3 +/- 4.9 micrograms/ml at 120 minutes after administration. Average myocardial CTX concentrations were 10.0 +/- 3.7 micrograms/g in group I, 3.6 +/- 2.1 micrograms/g in group II and 2.3 +/- 1.8 micrograms/g in group III. The myocardial/serum concentration ratio was 0.22 +/- 0.14 in group I, 0.15 +/- 0.08 in group II and 0.18 +/- 0.12 in group III, respectively. These results suggested that the serum and myocardial concentrations of CTX were high enough to be prophylactic and therapeutic against not only aerobic but also anaerobic and opportunistic infections during and after cardiac surgery.

Adult↗
PubMed1984

[Clinical evaluation of cefmenoxime in internal medicine, with special reference to infections associated with hematological disorders].

Clinical evaluation of cefmenoxime (CMX, Bestcall) was examined in the infection associated with hematological disorders, respiratory tract and other disorders. Clinical effectiveness for severe infection of hematological disorders was 47.4% in good and 84.2% in fair response, however, in the respiratory tract infections, 89.7% in good response was obtained. Opportunistic infection due to Gram-negative bacilli are often experienced in patients with hematological disorders. It was discussed that CMX would be a good therapeutic agent against infectious diseases associated with hematological disorders because it's antibacterial spectrum would be parallel to pathogens of such disorders.

Adolescent↗
PubMed1984

[Pharmacological studies of a new sleep-inducer, 1H-1,2,4-triazolyl benzophenone derivative (450191-S) (V). General pharmacological activities].

General pharmacological activities of 450191-S were studied in various species of animals and compared with those of reference benzodiazepines (BDZ). 450191-S at doses of 10 mg/kg slightly decreased (-5 degrees C) the rectal temperature of rabbits. 450191-S decreased respiratory and heart rates in anesthetized cats, but the effects were less than those of diazepam or triazolam. 450191-S increased respiratory and heart rates in conscious dogs, but had no effect on the blood pressure, electrocardiogram and autonomic nervous system in cats and dogs. The drug displayed a slight spasmolytic activity in the small intestine of guinea pigs and a slight inhibitory effect on isolated non-pregnant and pregnant uteri of rats. These effects were less than those of diazepam or nitrazepam. Below doses of 25 mg/kg, 450191-S did not affect urinary volume and electrolyte excretions in rats. It also decreased brain norepinephrine (NE) turnover rates in rats, but decreased NE and dopamine turnover rates in mice. These effects of 450191-S were less than those of nitrazepam. 450191-S was found to be minimally irritating to the ocular mucosa in rabbits and did not irritate the stomach and small intestine in rats. These effects were also compared with those of active metabolites of 450191-S, M-1, M-2, M-A, M-3 and M-4, and the superiority of the mother compound over its metabolites was clarified.

Animals↗
PubMed1984

[Treatment of complicated urinary tract infections caused by fungi].

The predisposing factors of funguria and the clinical efficacy of treatment with ketoconazole, a new oral imidazole antifungal drug were studied in 10 patients with complicated urinary tract infection due to fungi. Preceding antibiotic therapy, presence of indwelling catheter and malignant tumor were regarded as the important factors that predisposed to the fungal urinary tract infections. Patients received 200 mg of ketoconazole once a day for 5 to 14 days. Of the 9 patients in whom clinical efficacy of ketoconazole was evaluated, excellent response was obtained in 4 patients, moderate in 2 and poor in 3 patients. Of the 9 strains of fungi isolated before treatment, 6 strains or 67% were eradicated after treatment. Neither subjective nor objective side effects were observed in any of 10 patients receiving ketoconazole, and laboratory tests showed elevated BUN and serum creatinine in 1 patient. From the results obtained in this study, ketoconazole was regarded as useful in the treatment of complicated urinary tract infection due to fungi.

Administration, Oral↗